Doing its part to increase competition so as to lower drug prices, the FDA launched a new biosimilars education campaign this week aimed at health care providers. The campaign includes a biosimilars website and educational materials in the form of fact sheets and graphics that define key terms, describe the standards a biosimilar must meet, explain the FDA approval path for the follow-ons and provide information about the data the agency reviews to determine biosimilarity. As its next step to promote market acceptance of biosimilars, the FDA said it is planning additional research to learn more about the types of information prescribers need to properly communicate with their patients about the follow-ons.